Epigenetic Approaches: Emerging Role of Histone Deacetylase Inhibitors in Cancer Immunotherapy

摘要: Abstract Histone deacetylase inhibitors (HDI) have been largely known for their ability to induce cell cycle arrest and apoptosis of tumor cells, effects that translated into clinically significant antitumor activity against certain malignancies. In addition, there is now increasing evidence HDIs are also endowed with immunoregulatory properties. Interestingly, while some reports highlighted the anti-inflammatory these compounds, others shown pro-inflammatory triggered by in vitro vivo studies. Known targets histone deacetylases (HDACs), enzymes recruited gene promoters where they regulate transcription through modifications. Some HDACs, however, can deacetylate nonhistone proteins, indicating role HDACs biology goes beyond initial described on histones encompasses more complex regulatory functions. This complexity, along fact most HDI currently use pan-HDI (multiple HDAC targets), might explain divergent compounds. Given this conundrum, chapter we summarized current understanding expression/function specific immune knowledge providing important insights immunobiology paving way development selective potentially less toxic epigenetic-based approaches effectively harness responses.